News Releases

September 26, 2018
Urovant Sciences Ltd. Announces Pricing of Initial Public Offering
BASEL, Switzerland and IRVINE, Calif. , Sept. 26, 2018 /PRNewswire/ -- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today announced the pricing of its initial public offering of 10,000,000 common shares at
Additional Formats
August 28, 2018
Urovant Sciences Licenses Novel Gene Therapy for Overactive Bladder
There are no currently available FDA-approved gene therapy treatments for overactive bladder Urovant expects to initiate Phase 2 hMaxi-K study in 2019 BASEL, Switzerland and IRVINE, Calif., August 28, 2018/PRNewswire – Urovant Sciences, a clinical-stage biopharmaceutical company focused on
Additional Formats